{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Omuro A"],"funding":["National Cancer Institute/National Institute of Health","NCI NIH HHS"],"pubmed_abstract":["Background
Methotrexate-based chemoradiotherapy is effective in primary central nervous system lymphoma (PCNSL) but carries a risk of severe neurotoxicity. In a single-arm study, a regimen with methotrexate, procarbazine, vincristine and cytarabine was combined with rituximab (R-MPV-A) and substantially reduced doses of whole-brain radiotherapy (LD-WBRT), resulting in excellent progression-free survival (PFS) and overall survival (OS). Because R-MPV-A had never been tested without radiation, we sought to evaluate the efficacy of R-MPV-A with and without LD-WBRT, as well as determining if such low radiotherapy doses influenced disease control and/or neurotoxicity.Methods
Patients were randomized to receive R-MPV-A alone (Chemo arm) or combined with LD-WBRT (ChemoRT arm), giv"],"journal":["Neuro-oncology"],"pagination":["noaf221"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904153"],"repository":["biostudies-literature"],"pubmed_title":["Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma."],"pmcid":["PMC12904153"],"funding_grant_id":["U10 CA180868","U10 CA180822","U10CA180868","U10CA180822"],"pubmed_authors":["Wefel JS","Werner-Wasik M","Bovi JA","Lallana EC","Omuro A","Corn BW","Aneja S","Rogers CL","Donnelly ED","Correa D","Iwamoto FM","Struve TD","Rosenblum M","Grommes C","Mehta MP","Yu HM","DeAngelis LM","Peereboom DM","Polley MC","Won M"],"additional_accession":[]},"is_claimable":false,"name":"Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma.","description":"Background
Methotrexate-based chemoradiotherapy is effective in primary central nervous system lymphoma (PCNSL) but carries a risk of severe neurotoxicity. In a single-arm study, a regimen with methotrexate, procarbazine, vincristine and cytarabine was combined with rituximab (R-MPV-A) and substantially reduced doses of whole-brain radiotherapy (LD-WBRT), resulting in excellent progression-free survival (PFS) and overall survival (OS). Because R-MPV-A had never been tested without radiation, we sought to evaluate the efficacy of R-MPV-A with and without LD-WBRT, as well as determining if such low radiotherapy doses influenced disease control and/or neurotoxicity.Methods
Patients were randomized to receive R-MPV-A alone (Chemo arm) or combined with LD-WBRT (ChemoRT arm), giv","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-07-15T18:02:21.858Z","creation":"2026-07-08T03:08:24.488Z"},"accession":"S-EPMC12904153","cross_references":{"pubmed":["41189315"],"doi":["10.1093/neuonc/noaf221"]}}